Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium infantis-mediated herpes simplex virus thymidine kinase + ganciclovir
- Development stage
- Preclinical
- Lead developer
- Jiangnan University
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Gene Therapies, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intravenous
01
Overview
This experimental gene-directed enzyme prodrug therapy (GDEPT) utilizes genetically engineered anaerobic *Bifidobacterium infantis* bacteria to deliver the herpes simplex virus thymidine kinase (HSV-TK) gene specifically to the hypoxic environment of solid tumors. Following intravenous administration, the bacteria selectively colonize the tumor core, where they express the HSV-TK enzyme. The subsequent administration of the non-toxic prodrug ganciclovir (GCV) allows the HSV-TK enzyme to convert GCV into a toxic metabolite, ganciclovir triphosphate, which acts as a chain terminator during DNA synthesis, leading to apoptosis in surrounding cancer cells. This targeted approach, researched by institutions including Jiangnan University, Wuxi Children's Hospital, and Chongqing Medical University, aims to maximize anti-tumor efficacy while minimizing systemic toxicity. Preclinical studies have demonstrated potential efficacy in models of renal cell carcinoma, bladder cancer, and gastric cancer.
- Other names
- Bifidobacterium infantis-mediated HSV-TK/GCVB. infantis-mediated HSV-TK + GCVBifidobacterium infantis-mediated herpes simplex virus thymidine kinase/ganciclovir suicide gene system
02
Targets
POLA1 (DNA polymerase alpha)HSV-TK (Herpes simplex virus type 1 thymidine kinase (HSV1-TK))DNA
Beyond the preview
Go deeper on Bifidobacterium infantis-mediated herpes simplex virus thymidine kinase + ganciclovir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium infantis-mediated herpes simplex virus thymidine kinase + ganciclovir.